vs
FIRSTSUN CAPITAL BANCORP（FSUN）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是FIRSTSUN CAPITAL BANCORP的1.2倍（$127.1M vs $110.0M），过去两年再鼎医药的营收复合增速更高（20.8% vs 6.9%）
FirstSun Capital Bancorp是一家总部位于美国的金融控股公司，提供商业及个人贷款、存款产品、财富管理、财资解决方案等全面的银行金融服务，主要面向美国区域市场的个人消费者、中小企业及企业客户。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
FSUN vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.2倍
$110.0M
两年增速更快
ZLAB
近两年复合增速
6.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $110.0M | $127.1M |
| 净利润 | $21.6M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 19.6% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | -8.4% | — |
| 每股收益（稀释后） | $0.76 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSUNZLAB
| Q1 26 | $110.0M | — | ||
| Q4 25 | $110.2M | $127.1M | ||
| Q3 25 | $107.3M | $115.4M | ||
| Q2 25 | $105.6M | $109.1M | ||
| Q1 25 | $96.2M | $105.7M | ||
| Q4 24 | $98.7M | $108.5M | ||
| Q3 24 | $98.2M | $101.8M | ||
| Q2 24 | $96.2M | $100.1M |
净利润FSUNZLAB
| Q1 26 | $21.6M | — | ||
| Q4 25 | $24.8M | — | ||
| Q3 25 | $23.2M | $-36.0M | ||
| Q2 25 | $26.4M | $-40.7M | ||
| Q1 25 | $23.6M | $-48.4M | ||
| Q4 24 | $16.4M | — | ||
| Q3 24 | $22.4M | $-41.7M | ||
| Q2 24 | $24.6M | $-80.3M |
毛利率FSUNZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率FSUNZLAB
| Q1 26 | — | — | ||
| Q4 25 | 29.0% | -54.6% | ||
| Q3 25 | 26.4% | -42.3% | ||
| Q2 25 | 31.2% | -50.3% | ||
| Q1 25 | 30.9% | -53.3% | ||
| Q4 24 | 20.4% | -62.6% | ||
| Q3 24 | 29.1% | -66.6% | ||
| Q2 24 | 32.3% | -76.0% |
净利率FSUNZLAB
| Q1 26 | 19.6% | — | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 21.6% | -31.2% | ||
| Q2 25 | 25.0% | -37.3% | ||
| Q1 25 | 24.5% | -45.8% | ||
| Q4 24 | 16.6% | — | ||
| Q3 24 | 22.8% | -40.9% | ||
| Q2 24 | 25.5% | -80.2% |
每股收益（稀释后）FSUNZLAB
| Q1 26 | $0.76 | — | ||
| Q4 25 | $0.89 | $-0.05 | ||
| Q3 25 | $0.82 | $-0.03 | ||
| Q2 25 | $0.93 | $-0.04 | ||
| Q1 25 | $0.83 | $-0.04 | ||
| Q4 24 | $0.57 | $-0.09 | ||
| Q3 24 | $0.79 | $-0.04 | ||
| Q2 24 | $0.88 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $413.7M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $715.5M |
| 总资产 | $8.6B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FSUNZLAB
| Q1 26 | $413.7M | — | ||
| Q4 25 | $652.6M | $689.6M | ||
| Q3 25 | $659.9M | $717.2M | ||
| Q2 25 | $785.1M | $732.2M | ||
| Q1 25 | $621.4M | $757.3M | ||
| Q4 24 | $615.9M | $779.7M | ||
| Q3 24 | $573.7M | $616.1M | ||
| Q2 24 | $535.8M | $630.0M |
股东权益FSUNZLAB
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $715.5M | ||
| Q3 25 | $1.1B | $759.9M | ||
| Q2 25 | $1.1B | $791.7M | ||
| Q1 25 | $1.1B | $810.8M | ||
| Q4 24 | $1.0B | $840.9M | ||
| Q3 24 | $1.0B | $667.7M | ||
| Q2 24 | $996.6M | $704.2M |
总资产FSUNZLAB
| Q1 26 | $8.6B | — | ||
| Q4 25 | $8.5B | $1.2B | ||
| Q3 25 | $8.5B | $1.2B | ||
| Q2 25 | $8.4B | $1.2B | ||
| Q1 25 | $8.2B | $1.2B | ||
| Q4 24 | $8.1B | $1.2B | ||
| Q3 24 | $8.1B | $985.3M | ||
| Q2 24 | $8.0B | $987.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流FSUNZLAB
| Q1 26 | — | — | ||
| Q4 25 | $111.5M | $-26.0M | ||
| Q3 25 | $49.4M | $-32.0M | ||
| Q2 25 | $15.0M | $-31.0M | ||
| Q1 25 | $26.4M | $-61.7M | ||
| Q4 24 | $101.1M | $-55.8M | ||
| Q3 24 | $48.1M | $-26.8M | ||
| Q2 24 | $20.9M | $-42.2M |
自由现金流FSUNZLAB
| Q1 26 | — | — | ||
| Q4 25 | $104.0M | $-26.7M | ||
| Q3 25 | $47.6M | $-35.0M | ||
| Q2 25 | $13.0M | $-33.9M | ||
| Q1 25 | $24.3M | $-63.2M | ||
| Q4 24 | $95.7M | $-58.4M | ||
| Q3 24 | $47.1M | $-28.2M | ||
| Q2 24 | $19.9M | $-42.9M |
自由现金流率FSUNZLAB
| Q1 26 | — | — | ||
| Q4 25 | 94.3% | -21.0% | ||
| Q3 25 | 44.4% | -30.4% | ||
| Q2 25 | 12.3% | -31.1% | ||
| Q1 25 | 25.3% | -59.9% | ||
| Q4 24 | 97.0% | -53.8% | ||
| Q3 24 | 47.9% | -27.7% | ||
| Q2 24 | 20.6% | -42.9% |
资本支出强度FSUNZLAB
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 0.5% | ||
| Q3 25 | 1.6% | 2.6% | ||
| Q2 25 | 1.9% | 2.6% | ||
| Q1 25 | 2.1% | 1.5% | ||
| Q4 24 | 5.5% | 2.4% | ||
| Q3 24 | 1.1% | 1.3% | ||
| Q2 24 | 1.1% | 0.7% |
现金转化率FSUNZLAB
| Q1 26 | — | — | ||
| Q4 25 | 4.49× | — | ||
| Q3 25 | 2.13× | — | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 1.12× | — | ||
| Q4 24 | 6.18× | — | ||
| Q3 24 | 2.15× | — | ||
| Q2 24 | 0.85× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
